ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Milano, Lombardia, ITA:

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Active, not recruiting
Multiple Myeloma
Drug: Carfilzomib
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Milan, Italy and 48 other locations

This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine...

Enrolling
Smoldering Multiple Myeloma
Drug: Elranatamab

Phase 2

Stichting European Myeloma Network

Pavia, Italy and 24 other locations

This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and pre...

Enrolling
Multiple Myeloma
Drug: NMS-03597812
Drug: NMS-03597812 + dexamethasone

Phase 1

Nerviano Medical Sciences

Milan, Lombardia, Italy and 5 other locations

order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple...

Active, not recruiting
Multiple Myeloma (MM)
Drug: WHG626
Biological: WVT078

Phase 1

Novartis
Novartis

Milano, MI, Italy and 11 other locations

CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: PHE885

Phase 2

Novartis
Novartis

Milano, MI, Italy and 37 other locations

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

Milan, Italy and 126 other locations

low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple...

Active, not recruiting
Multiple Myeloma
Drug: Selinexor
Drug: Dexamethasone

Phase 3

Karyopharm Therapeutics
Karyopharm Therapeutics

Milan, Italy and 156 other locations

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered a...

Active, not recruiting
Multiple Myeloma
Anemia
Drug: INCB000928

Phase 1, Phase 2

Incyte
Incyte

Rozzano, Italy and 14 other locations

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Lenalidomide

Phase 3

Pfizer
Pfizer

Milano, Lombardia, Italy and 210 other locations

phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination o...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Milano, Italy and 40 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems